New Frontiers in the Treatment of Diabetic Dyslipidemia

Article View

The Review of Diabetic Studies,2013,10,2-3,204-212.
Published:August 2013
Type:Review Article
Author(s) affiliations:

Shu-Yi Wang1, Ming-Chia Hsieh1,2 , Shih-Te Tu1, and Chieh-Sen Chuang3,4

1Departments of Endocrinology and Metabolism, Changhua Christian Hospital, Changhua, TAIWAN.

2Graduate Institute of Integrated Medicine, China Medical University, TAIWAN.

3Departments of Neurology, Changhua Christian Hospital, Changhua, TAIWAN.

4Department of Life Sciences, National Chung-Hsing University, Taichung City, TAIWAN.


Dyslipidemia is a major risk factor for cardiovascular complications in people with diabetes. Lowering low-density lipoprotein cholesterol (LDL-C) levels is effective in the primary and secondary prevention of diabetic vascular complications. However, LDL-C levels do not reflect all aspects of diabetic dyslipidemia, which is characterized by hypertriglyceridemia and low high-density lipoprotein cholesterol (HDL-C). Statins, nicotinic acid, and fibrates play a role in treating diabetic dyslipidemia. Atherosclerosis is a major disorder of the blood vessel wall in patients with diabetes. A number of antihyperlipidemic agents may be beneficial and exhibit effects at the actual site of vascular disease and not only on plasma lipoprotein concentrations. Several novel therapeutic compounds are currently being developed. These include additional therapeutics for LDL-C, triglycerides, HDL-C, and modulators of inflammation that can be used as possible synergic agents for the treatment of atherosclerosis and irregularities in plasma lipoprotein concentrations.